Skip main navigation (Press Enter).
Log in
Toggle navigation
Education & Science
SITC 2026 - 41st Annual Meeting & Pre-Conference Programs
Past and Future Annual Meetings
Advances in Cancer Immunotherapy
SITC Webinar on Bispecifics and T cell Engagers
SITC Biotech Initiative
SITC 2026 EU Immuno-Oncology Drug Development Summit
SITC Neoadjuvant Initiatives
Cancer Immunotherapy Winter School
Spring Scientific
Collaborative Education Programs
Patient & Survivor Resources
Webinars and Virtual Workshops
Upcoming Events
Career Development
Certificate in Cancer Immunotherapy
Fellowships
NCI Immunotherapy Fellowship
Women in Cancer Immunotherapy Network
Sparkathon
SITC Clinical Immuno-Oncology Network (SCION) Workshop
Clinical Trials Training and Resources
Early Career Scientist (ECS) Committee
Path to SITC Leadership
Publications & Guidelines
Journal for ImmunoTherapy of Cancer
SITC Clinical Practice Guidelines
SITC Immunotherapy Books
SITC Scientific Publications News
About
Mission & Vision
Strategic Initiatives
Strategic Plan
Elevating a Rich Oncology Community
Board of Directors
Committees, Task Forces, & Communities
Awards and Recognition
40th Anniversary Awards
Academy of Immuno-Oncology
SITC Policies
Contact SITC
SITC News
Cancer Immunotherapy Month
Get Involved
Join SITC
Connect-a-Colleague
Corporate Membership
International Membership
Member Directory
Support SITC
Policy & Advocacy
Committees, Task Forces, & Communities
Career Connections
Volunteer with SITC
SITC Resource Library
Events
For Patients
Log in
Join SITC or renew your membership to take advantage of exclusive benefits through 2026 or 2027!
SITC Guidelines News
×
Community Home
Discussion
0
Library
0
Blogs
37
Events
0
Members
2
last person joined: 3 years ago
News posts for SITC Cancer Immunotherapy Guidelines
SITC Clinical Practice Guideline on Immune Checkpoint Inhibitor-related Adverse Events Published in JITC
By
SITC Scientific Publications News
posted
06-25-2021 00:00
Like
The
“
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
”
was published
in
JITC
June
25, 2021.
While ICIs have improved patient outcomes in a number of clinical settings, the same mechanisms that underpin their effective anti-tumor properties may cause unique toxicities, specifically immune-related adverse events (
irAEs
). As ICIs increasingly become integrated into treatment plans for an ever-increasing number of disease settings, there is a need for clear, expert guidance on the recognition and management of
irAEs
.
SITC convened an
expert panel
to develop this clinical practice guideline with evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and improve outcomes for patients.
June 25, 2021
0 comments
10 views
Related Content
ICI-Related Adverse Events CPG Updates v1.1 and v1.2 Now Available
SITC Scientific Publications News
Added 07-18-2024
Blog Entry
SITC Clinical Practice Guideline on Immunotherapy for the Treatment of Urothelial Cancer Published in JITC
SITC Scientific Publications News
Added 07-15-2021
Blog Entry
SITC Clinical Practice Guideline on Immunotherapy for the Treatment of Hepatocellular Carcinoma Published in JITC
SITC Scientific Publications News
Added 09-12-2021
Blog Entry
New Guideline Information and Tools Available – Lymphoma, RCC, ICI-rAEs, Urothelial Cancer & Prostate Cancer
SITC Scientific Publications News
Added 11-09-2022
Blog Entry
New SITC Melanoma CPG Published in JITC
SITC Scientific Publications News
Added 10-18-2023
Blog Entry
Permalink
https://www.sitcancer.org/blogs/sitc-guideline-news/2021/06/25/sitc-cpg-ici-r-ae
Copyright 2025. All rights reserved.
Powered by Higher Logic